- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05994235
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
A Phase II Trial of Tazemetostat Plus Mosunetuzumab in Untreated Follicular Lymphoma
The goal of this study is to learn about the safety and effectiveness of the combination of tazemetostat pills in combination with mosunetuzumab injections for people with follicular lymphoma who haven't received treatment before. The investigators hypothesize that tazemetostat with mosunetuzumab has the potential to increase the efficacy of the product without compromising the safety.
Tazemetostat is a drug that inhibits EZH2, an enzyme known to drive the development of B-cell lymphomas, and inhibiting it appears to have many effects that slow down lymphoma growth and enhance the immune system's ability to fight it. Tazemetostat is FDA-approved in previously treated follicular lymphoma and currently undergoing study in other lymphomas.
Mosunetuzumab is a bispecific antibody therapy that is a therapeutic strategy that uses the immune system to fight lymphoma, called immunotherapy. Bispecific antibodies have two ends: one attaches to T cells in the immune system and the other attaches to lymphoma cells, helping guide our immune system to attack the cancer. Mosunetuzumab has been studied in follicular lymphoma that has previously been treated, with positive results. Mosunetuzumab is approved by the FDA to be given intravenously (directly into a vein) but is not yet approved by the FDA is not yet approved as an injection under the skin, which is how it is given in this study. They have not yet been studied in combination.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Tejasvi Kaur Sahni
- Phone Number: 646-962-9337
- Email: tks4001@med.cornell.edu
Study Contact Backup
- Name: Brittany Hobbie
- Email: brh4008@med.cornell.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Weill Cornell Medicine/NewYork-Presbyterian Hospital
-
Contact:
- Brittany Hobbie
- Email: brh4008@med.cornell.edu
-
Principal Investigator:
- Samuel Yamshon, M.D.
-
Contact:
- Tejasvi Kaur Sahni
- Email: tks4001@med.cornell.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to comply with the study protocol
- Willing to use highly effective contraception, if of childbearing potential
- Diagnosed with follicular lymphoma (FL; Grades 1-3a)
- Received no prior systemic lymphoma therapy (local radiotherapy is not considered systemic therapy)
Exclusion Criteria:
- Inability to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, vomiting) that might impair the bioavailability of tazemetostat
- Grade 3b FL
- History of transformation of indolent disease to diffuse large B cell lymphoma
- Any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or myeloproliferative neoplasm (MPN)
- Any prior history of T cell lymphoblastic lymphoma (T-LBL)/ T cell lymphoblastic leukemia (T-ALL)
- Active or history of central nervous system lymphoma or leptomeningeal infiltration
- Prior standard or investigational systemic anti cancer therapy for lymphoma. Patients who have received prior XRT will not be excluded
- History of solid organ transplantation
- History of severe allergic or anaphylactic reaction to humanized, chimeric or murine monoclonal antibodies (MAbs)
- Known or suspected chronic active Epstein-Barr virus (EBV) infection
- Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
- Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis
- Active Hepatitis B or Hepatitis C infection
- HIV positive with CD4 count <200 and not currently taking antiretroviral therapy
- History of progressive multifocal leukoencephalopathy (PML)
- Active autoimmune disease requiring treatment
- History of autoimmune disease, including, but not limited to: myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
- Prior allogeneic stem cell transplant (SCT)
- Significant cardiovascular disease (e.g., New York Heart Association Class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina) or significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)
- Major surgery other than for diagnosis within 28 days prior to Day 1 of Cycle 1 Day 1 or anticipation of a major surgical procedure during the course of the study
- Active central nervous system disease or underlying neurologic disease such as stroke or intracranial hemorrhage within 3 months prior to enrollment, history of seizure disorder, or history of neurogenerative disease
- History of pneumonitis or interstitial lung disease
- Pregnant or breastfeeding or intending to become pregnant during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Subcutaneous Mosunetuzumab and Oral Tazemetostat
50 patients will be enrolled and treated with standard dosing of subcutaneous mosunetuzumab, and with oral tazemetostat by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation.
|
Mosunetuzumab will be administered in weekly dose increments ("step-up dosing") during Cycle 1 and then on Day 1 of each cycle.
Mosunetuzumab will be given in 28-day cycles for up to 12 cycles.
Mosunetuzumab will be administered SC at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15 in Cycle 1. Beginning with Cycle 2, it will be administered SC at the dose of 45 mg on Day 1.
Each cycle lasts 4 weeks.
Oral tazemetostat will be administered by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation until disease progression, unacceptable toxicity, or consent is withdrawn.
Patients will remain on tazemetostat for up to twelve 28-day cycles from initiation of mosunetuzumab.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants who achieve a complete response (CR) by completion of therapy, as determined by the Lugano Criteria
Time Frame: Estimated day 336
|
The proportion of patients who achieve complete response as per the Lugano criteria will be calculated and their 90% confidences will be computed with Clopper-Pearson method via exact binomial distribution.
|
Estimated day 336
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants who experience cytokine release syndrome (CRS)
Time Frame: Day 0 to Day 28
|
CRS will be assessed per American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading
|
Day 0 to Day 28
|
Number of participants who experience Immune effector cell-associated neurotoxicity syndrome (ICANS)
Time Frame: Day 0 to Day 28
|
ICANS will be assessed per American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading
|
Day 0 to Day 28
|
Median Progression-Free Survival (PFS)
Time Frame: For a maximum of approximately 10 years
|
PFS is defined as the duration of time from start of treatment to time of progression or death from any cause.
Patients will be followed for a maximum of approximately 10 years from the start of treatment.
|
For a maximum of approximately 10 years
|
Median Overall Survival (OS)
Time Frame: For a maximum of approximately 10 years
|
OS is defined as the duration of time from start of treatment to death from any cause.
Patients will be followed for a maximum of approximately 10 years from the start of treatment.
|
For a maximum of approximately 10 years
|
Objective Response Rate (ORR) at the time of therapy completion, as defined by Lugano Criteria
Time Frame: Estimated to be day 336
|
ORR is defined as the proportion of patients who have a partial or complete response to therapy
|
Estimated to be day 336
|
Number of participants who achieve a Complete Response (CR) per Lugano's Criteria
Time Frame: For a maximum of approximately 10 years
|
Response and progression are evaluated according to the Lugano criteria for lymphoma response.
|
For a maximum of approximately 10 years
|
Median Duration of Response
Time Frame: For a maximum of approximately 10 years
|
The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease or death due to any cause, whichever occurs first is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).
|
For a maximum of approximately 10 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Samuel Yamshon, M.D., Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-06026184
- 22-10025285 (Other Identifier: WCM IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Follicular Lymphoma
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Epizyme, Inc.RecruitingFollicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular LymphomaUnited States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGrade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...United States
-
Massachusetts General HospitalTG TherapeuticsTerminatedLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
Clinical Trials on Mosunetuzumab
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Follicular LymphomaUnited States
-
Genentech, Inc.RecruitingNon-Hodgkin LymphomaUnited States, Puerto Rico
-
Hoffmann-La RocheActive, not recruitingSystemic Lupus ErythematosusUnited States, Poland, Georgia, Moldova, Republic of
-
M.D. Anderson Cancer CenterGenentech, Inc.WithdrawnRefractory B-cell Acute Lymphoblastic LeukemiaUnited States
-
Washington University School of MedicineGenentech, Inc.RecruitingDiffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed B-Cell Lymphoma | Follicular Lymphoma Grade 3BUnited States
-
Hoffmann-La RocheActive, not recruitingDiffuse Large B-cell LymphomaUnited States, Israel, Spain, Korea, Republic of, Poland, Taiwan
-
Washington University School of MedicineGenentech, Inc.RecruitingB Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | Aggressive Lymphoma | Follicular Lymphoma Grade 3United States
-
Genentech, Inc.Active, not recruitingLymphocytic Leukemia, Chronic | Lymphoma, Non HodgkinUnited States, Korea, Republic of, Australia, United Kingdom, Germany, Canada, Spain
-
Hoffmann-La RocheActive, not recruitingB-cell Non-Hodgkin LymphomaUnited States, Canada, Belgium, Spain, United Kingdom
-
Hoffmann-La RocheRecruitingChronic Lymphocytic LeukemiaSpain, Australia, Germany, United States, Italy, United Kingdom, France